

MENSTRUAL CYCLE-RELATED CHANGES IN BLOOD SERUM TESTOSTERONE AND ESTRADIOL LEVELS AND THEIR RATIO STABILITY IN YOUNG HEALTHY FEMALES

*Popova L.¹, Vasylyeva L.¹, Tkachenko A.¹, Polikarpova H.¹,
Kokbas U.², Tuli A.², Kayrin L.³, Nakonechna A.¹*

¹Kharkiv National Medical University, Ukraine

²Çukurova University, the Republic of Turkey;

³University of Kyrenia, the Republic of Turkey

<https://doi.org/10.35339/ic.6.3.155-161>

Abstract

The role of testosterone in females has not been fully elucidated. Studies usually involved postmenopausal women. Literature data on age-related changes of testosterone levels are contradictory. The application of sex hormones and their combination in medical practice increases the importance of study of the menstrual cycle fluctuations in testosterone, populational variability of testosterone and estradiol levels and their ratio in healthy females to prevent the excessive doses of sex steroids and provide the using of optimal their doses in different phases of menstrual cycle during treatment. The objective of our research was to evaluate testosterone and estradiol levels, their interrelation and their ratio in different stages of menstrual cycle in young healthy women. Twenty-two young Ukrainian females aged 18 to 22 years were enrolled in this study. Testosterone and estradiol levels in blood serum were determined by Estradiol ELISA and Testosterone ELISA kits (Italy). Both estradiol and testosterone levels depended on menstrual cycle phases. The highest testosterone level was revealed in ovulation. No correlation between blood serum testosterone and estradiol levels was found in all menstrual cycle phases. Differences in testosterone and estradiol levels between Ukrainian women and some other populations of women were noted, indicating that such differences must be taken into account when treating women of different populations. Testosterone/estradiol ratio was not changed during menstrual cycle. Because of the constancy of the ratio of testosterone to estradiol during menstrual cycle and the age-related change in that ratio, this must be taken into account in the treatment of elderly women in order to create a testosterone-estradiol ratio that is characteristic of young women.

Key words: *Testosterone, estradiol, menstrual cycle phases, women.*

Introduction

Testosterone is an essential hormone for women [1, 2]. Its physiological effects are mediated directly or via aromatization to estradiol in peripheral tissues [1]. However, little attention has been paid to functions of endogenous androgens in females [3]. Conclusions about roles of endogenous androgens are usually based on clinical investigations [1, 4–6] or on data obtained

on postmenopausal women [3, 7–9]. Information on healthy young women is scarce [10–12]. Moreover, age-related changes in blood testosterone levels have been demonstrated. However, data on the dynamics of such changes are contradictory [3]. Testosterone and estradiol and their combination are used not only in female sexual dysfunction [13, 14], but also may become a new therapeutic strategy in depression [15]. However the menstrual cycle-related fluctuations of testosterone, populational variability of testosterone and estradiol levels and their ratio in healthy females remain insufficiently investigated. These studies are necessary to prevent the excessive doses of sex steroids and

Corresponding Author:

Liudmyla Popova, PhD, DrSc, Professor,

Department of Biochemistry,

Kharkiv National Medical University, Ukraine.

E-mail: popova_ld@ukr.net

to provide the physiological menstrual cycle-related fluctuations during the treatment.

2. Purposes, subjects and methods:

2.1. Purpose

Given the facts mentioned above, the aim of our study was to assess testosterone and estradiol levels, their interrelation and their ratio in different stages of menstrual cycle in young healthy females.

2.2. Subjects & Methods

The study comprised 22 young healthy Ukrainian women aged 18 to 22 years with body mass index of 19–24. All females had the regulatory 28–32-day-long menstrual cycle. They had no surgery and traumas in anamnesis. They have not been taking contraceptives and medicines that may affect their hormonal profile by any way for last 3 months. Blood samples were collected 3 times: in follicular, ovulation and luteal phases of menstrual cycle at the same time of day (8.00–9.00 a.m.). Blood serum was prepared and used for testosterone and estradiol level determination.

Testosterone and estradiol levels in blood serum were determined by Estradiol ELISA and Testosterone ELISA kits purchased from *DiaMetra* (Italy). Both kits were based on the quantitative sandwich enzyme immunoassay technique. All procedures were carried out in accordance with the instructions provided by the manufacturer. As soon as the color development was stopped, the optical density of the solutions was determined with the help of the Awareness Technology Stat Fax 303 Plus Microstrip Reader (USA). Testosterone concentrations in blood serum were expressed in nmol/l, while the level of estradiol was expressed in pmol/l.

All procedures and manipulations were carried out in accordance with the ethical standards of the Committee of Ethics and Bioethics of Kharkiv National Medical University and the revised Declaration of Helsinki (2000). All subjects signed a written informed consent.

Statistical analysis was performed using nonparametric statistical methods for dependent variables with the help of the *Statistica* 6.0 software (StatSoft, USA). A nonparametric analogue of the dispersion analysis - the Friedman ANOVA test – was used to reveal the dependence of parameters on the menstrual cycle phase. Wilcoxon test was used to compare parameters in various phases of the cycle. Correlation analysis according to Spearman was used to compare parameters of the same group.

Conflict of interests

The authors declare that they have no competing interests.

3. Results and discussion

In order to detect the dependence of the content of sex hormones on the phases of the menstrual cycle, we used a Friedman ANOVA test. Friedman ANOVA test is a nonparametric alternative to one-way repeated measures analysis of variance. According to our results, both estradiol and testosterone levels depended on the menstrual cycle phases: Chi Sqr. = 8,000000, $p < 0.01832$ for testosterone; Chi Sqr. = 6,888889, $p < 0.03192$ for estradiol.

No correlation between blood serum testosterone and estradiol levels was found in all menstrual cycle phases.

The highest β -estradiol level was observed in ovulation (*Fig. 1*). The differences between estradiol levels in ovulation and the follicular phase, in ovulation and the luteal phase were statistically significant ($p = 0.003511$ and $p = 0.012793$, respectively). The difference between estradiol levels in the follicular and luteal phases was statistically insignificant ($p = 0.656642$).




Fig. 1. β -Estradiol levels (pmol/l) in blood serum of women in different phases of the menstrual cycle (Me [25%; 75%], min and max; * – $p < 0.05$ versus the ovulation phase)

Follicular phase: testosterone Mean+St.Dev. 0.3286+0.1491 nmol/l; estradiol Mean+St.Dev. 121.7629+33.0308 pmol/l; testosterone/estradiol ratio 2.69.

Ovulation phase: testosterone Mean+St.Dev. 0.5476+0.192 nmol/l; estradiol Mean+St.Dev. 244.1746+138.949 pmol/l; testosterone/estradiol ratio 2.91.

Luteal phase: testosterone Mean+St.Dev. 0.4251+0.2384 nmol/l; estradiol Mean+St.Dev. 122.1754+30.2833 pmol/l; testosterone/estradiol ratio 3.58.

The highest testosterone level was revealed in ovulation (*Fig. 2*). The difference between testosterone levels in the follicular and ovulation




Fig. 2. Testosterone levels (nmol/l) in blood serum of women in different phases of the menstrual cycle (Me [25%; 75%], min and max; * – $p < 0.05$ versus the ovulation phase)

phases was significant ($p = 0.002162$). The differences between testosterone levels in the follicular and luteal phases, in ovulation and luteal phases were almost significant ($p = 0.062$).

The differences between the testosterone/estradiol ratios in various phases of the menstrual cycle were insignificant.

Discussion. The β -estrogen level was higher in Ukrainian women compared with the Norwegian ones [10] and lower than in Chinese [16] or Greek [5] population. The testosterone level was lower in women of Ukrainian origin in comparison with the Norwegian [10], Spanish [16] or Greek [5] women. Our findings of population differences in the testosterone and estradiol levels suggests that such differences must be taken into account when interpreting data during medical tests and discussing the findings of scientific researches.

Our findings concerning the dynamics of estradiol during the menstrual cycle correspond to the data of other researchers. In particular, the levels of estradiol in the follicular and luteal phases did not differ [16]. Estradiol peak was observed in ovulation.

According to our data, not only estradiol but also testosterone levels depend on the menstrual cycle phases. Similarly to estradiol, the peak of testosterone was observed during ovulation. As in the case of estradiol, there was no difference in the content of testosterone in the follicular and luteal phases. Unlike estradiol, differences in testosterone levels during ovulation and in the luteal phase were insignificant. Statistically significant elevation of mid-cycle testosterone concentrations was found by other authors, but they believe that that elevation is not clinically relevant since day-to-day variation is higher and

independent of the menstrual cycle [17]. The peak of testosterone in ovulation may be due to a control of androgen production by luteinizing hormone in gonadotropin-dependent stages of folliculogenesis [18].

In our study, the testosterone/estradiol ratio was not changed during the menstrual cycle. According to our data, testosterone levels in women are on average 3 times higher than the estradiol level. It has been reported that the testosterone level exceeds the estradiol content in blood serum dozens-fold, but this difference is observed in the elderly women [5]. At the same time, a decrease in the content of both hormones is observed, but the estradiol level is reduced more noticeably.

Higher levels of testosterone compared with estradiol in women, dependence of testosterone levels on the menstrual cycle, the presence of androgen receptors in woman, and the localization of androgen receptor gene on the X chromosome [5] suggest that testosterone performs certain functions in females.

Only several researches have focused on the role of testosterone in healthy women. Thus, information on this subject is limited. In particular, it has been demonstrated that endogenous testosterone levels correlate positively with amygdala reactivity in female adolescents and middle-aged women. After receiving a single nasal dose of testosterone, the amygdala reactivity in the middle-aged women rapidly increases to a level comparable to the young women [19]. Exogenous testosterone attenuates the integrated central stress response in healthy young females [12]. Authors believe that androgens promote dynamic regulation of the stress system via central neuropeptidergic pathways that control corticotropin-releasing hormone and arginine vasopressin expression. A research performed on the androgen receptor knockout female mice revealed that the androgen receptors have a functional role in neuroendocrine regulation and timing of the ovulatory luteinizing hormone surge as well as the antral/preovulatory follicle development [20].

Most of the data on the role of testosterone in the body of women was obtained in clinical studies. Such findings are frequently contradictory.

Different authors have opposite opinions about the testosterone influence on depression development. According to some of them, testosterone prevents the development of depression, since the low testosterone levels are

observed in depressed women compared with women in the control group and its elevated levels are found after pharmacotherapy [4]. On the other hand, it has been shown that testosterone does not influence the depression development [21] or even worsens symptoms of depression [22].

According to some clinical studies, exogenous testosterone enhances cognitive performance and improves musculoskeletal health in postmenopausal women [1]. However, the other researches do not support the hypothesis that increasing testosterone concentrations prevent cognitive decline in men and women over 65 years of age [23]. Moreover, the results of other studies support the hypothesis that the free testosterone has a sex-specific impact on cognitive performance. Positive correlation between free testosterone levels and visual-spatial abilities, semantic memory, and episodic memory, with greater positive influence with increasing age was demonstrated in males. In women, free testosterone negatively correlated with verbal fluency, semantic memory, and episodic memory [24]. It has been reported in another study that in older women the endogenous testosterone has a negative association with verbal memory, which is usually one of the first functions to decline in dementia [6]. Some functions of testosterone in women are provided by its conversion to estradiol. This reaction is catalyzed by aromatase. In the hippocampus, it is upregulated in postmenopausal women and downregulated in Alzheimer's disease [25].

Although not all the effects of testosterone in females are provided by its transformation into estradiol. This is indirectly evidenced by our data

on the lack of correlation between the testosterone and estradiol levels in the blood serum.

Obviously, the optimal ratio between testosterone and estradiol is of huge importance, which is indirectly confirmed by the constancy of this ratio throughout the menstrual cycle. It is also confirmed by literature data. It is believed that relative but not absolute levels of sex hormones play more important role in etiology of depression [26]. According to Huang Y et al. (2019), in men the testosterone/estradiol ratio correlated significantly with age, human leukocyte telomerase reverse transcriptase mRNA levels, telomerase activity of peripheral blood mononuclear cells and telomere length [27].

Conclusions

The level of testosterone in blood serum of young women depends on the phase of the menstrual cycle. Population differences in the testosterone and estradiol levels suggests that such differences must be taken into account during treatment of women from different populations.

No correlation between serum levels of testosterone and estradiol in all phases of the menstrual cycle is found indirectly indicating that testosterone in females has specific functions not associated with its conversion to estradiol.

The testosterone/estradiol ratio does not depend on the menstrual cycle phase. The age-related changes in the testosterone/estradiol ratio should be taken into account in the older women treatment in order to create the optimal the testosterone/estradiol ratio characteristic for young women from the same population.

References

1. Davis SR, Wahlin-Jacobsen S. (2015). Testosterone in women--the clinical significance. *Lancet Diabetes Endocrinol.* 2015;3(12):980–92. doi: 10.1016/S2213-8587(15)00284-3. PMID: 26358173.
2. Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. (2016). Androgens and Female Sexual Function and Dysfunction--Findings From the Fourth International Consultation of Sexual Medicine. *J Sex Med.* 2016;13(2):168–78. doi: 10.1016/j.jsxm.2015.12.033. PMID: 26953831.
3. Yasui T, Matsui S, Tani A, Kunimi K, Yamamoto S, Irahara M. (2012). Androgen in postmenopausal women. *J Med Invest.* 2012;59(1-2):12–27. PMID: 22449989.
4. Kumsar S, Kumsar NA, Saglam HS, Kose O, Budak S, Adsan O. (2014). Testosterone levels and sexual function disorders in depressive female patients: effects of antidepressant treatment. *J Sex Med.* 2014;11(2):529–35. doi: 10.1111/jsm.12394. PMID: 24286389.
5. Glaser R, Dimitrakakis C. (2013). Testosterone therapy in women: Myths and misconceptions. *Maturitas.* 2013; 74(3):230–4. doi: 10.1016/j.maturitas.2013.01.003. PMID: 23380529.
6. Hogervorst E. (2012). Prevention of dementia with sex hormones: a focus on testosterone and cognition in women. *Minerva Med.* 2012; 103(5):353–9. PMID: 23042370.
7. Lambrinoudaki I, Christodoulakos G, Rizos D, Economou E, Argeitis J, Vlachou S, Creatsa M, Kouskouni E, Botsis D. (2006). Endogenous sex hormones and risk factors for atherosclerosis in healthy

Greek postmenopausal women. *Eur J Endocrinol.* 2006;154(6):907–16. PMID: 16728552 DOI: 10.1530/eje.1.02167.

8. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosner BA, Colditz GA, Hankinson SE. (2010). The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. *Int J Cancer.* 2010;126(1):199–207. doi: 10.1002/ijc.24709. PMID: 19569181.

9. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR, Buring JE. (2003). Sex hormone levels and risk of cardiovascular events in postmenopausal women. *Circulation.* 2003; 108(14):1688–93. PMID:12975257.

10. Pintzka CW, Evensmoen HR, Lehn H, Haberg AK. (2016). Changes in spatial cognition and brain activity after a single dose of testosterone in healthy women. *Behav Brain Res.* 2016;298 (Pt B):78–90. doi: 10.1016/j.bbr.2015.10.056. PMID: 26542812

11. Tajima-Pozo K, Bayon C, Diaz-Marsa M, Carrasco JL. (2015). Correlation between personality traits and testosterone concentrations in healthy population. *Indian J Psychol Med.* 2015; 37(3): 317–321. doi: 10.4103/0253-7176.162956

12. Hermans EJ, Putman P, Baas JM, Gecks NM, Kenemans JL, van Honk J. (2007). Exogenous testosterone attenuates the integrated central stress response in healthy young women. *Psychoneuroendocrinology.* 2007;32(8–10):1052–61. PMID:17904297

13. Palacios S. (2007). Androgens and female sexual function. *Maturitas.* 2007; 57(1):61–5. PMID: 17368976 DOI:10.1016/j.maturitas.2007.02.014

14. Bolour S, Braunstein G. (2005). Testosterone therapy in women: a review. *Int J Impot Res.* 2005;17(5):399–408. PMID:15889125 DOI:10.1038/sj.ijir.3901334

15. Peng R, Dai W, Li Y. (2018). Neuroprotective effect of a physiological ratio of testosterone and estradiol on corticosterone-induced apoptosis in PC12 cells via Traf6/TAK1 pathway. *Toxicol In Vitro.* 2018;50:257–263. doi: 10.1016/j.tiv.2018.03.018. PMID:29625166

16. Bai X, Li J, Zhou L, Li X. (2009). Influence of the menstrual cycle on nonlinear properties of heart rate variability in young women. *Am J Physiol Heart Circ Physiol.* 2009;297(2):H765–74. doi: 10.1152/ajpheart.01283.2008. PMID: 19465541.

17. Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC. (2013). Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. *Steroids.* 2013;78(1):96–101. doi: 10.1016/j.steroids.2012.10.010. PMID:23127814.

18. Palermo R. (2007). Differential actions of FSH and LH during folliculogenesis. *Reprod Biomed Online.* 2007;15:326–337. doi: 10.1016/S1472-6483(10)60347-1. PMID:17854533.

19. van Wingen GA, Zyllicz SA, Pieters S, Mattern C, Verkes RJ, Buitelaar JK, Fernandez G. (2009). Testosterone increases amygdala reactivity in middle-aged women to a young adulthood level. *Neuropsychopharmacology.* 2009;34(3):539–47. doi: 10.1038/sj.npp.2008.2. PMID:18235425.

20. Cheng XB, Jimenez M, Desai R, Middleton LJ, Joseph SR, Ning G, Allan CM, Smith JT, Handelsman DJ, Walters KA. (2013). Characterizing the neuroendocrine and ovarian defects of androgen receptor-knockout female mice. *Am J Physiol Endocrinol Metab.* 2013;305(6):E717–26. doi: 10.1152/ajpendo.00263.2013. PMID:23880317.

21. Gallicchio L, Schilling C, Miller SR, Zacur H, Flaws JA. (2007). Correlates of depressive symptoms among women undergoing the menopausal transition. *J Psychosom Res.* 2007;63(3):263–8. PMID:17719363.

22. Bromberger JT, Schott LL, Kravitz HM, Sowers M, Avis NE, Gold EB, Randolph JF Jr, Matthews KA. (2010). Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). *Arch Gen Psychiatry.* 2010;67(6):598–607. doi: 10.1001/archgenpsychiatry.2010.55. PMID:20530009.

23. Hogervorst E, Matthews FE, Brayne C. (2010). Are optimal levels of testosterone associated with better cognitive function in healthy older women and men? *Biochim Biophys Acta.* 2010;1800(10):1145–52. doi: 10.1016/j.bbagen.2009.12.009. PMID:20060437.

24. Thilers PP, Macdonald SW, Herlitz A. (2006). The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. *Psychoneuroendocrinology.* 2006;31(5):565–76. PMID:16487665 DOI:10.1016/j.psyneuen.2005.12.005.

25. Butler HT, Warden DR, Hogervorst E, Ragoussis J, Smith AD, Lehmann DJ. (2010). Association of the aromatase gene with Alzheimer's disease in women. *Neurosci Lett.* 2010;468(3):202–6. doi: 10.1016/j.neulet.2009.10.089. PMID: 19879925

26. Swaab DF, Bao AM, Lucassen PJ. (2005). The stress system in the human brain in depression and neurodegeneration. *Ageing Res Rev.* 2005;4(2):141–94. PMID:15996533 DOI:10.1016/j.arr.2005.03.003

27. Huang Y, Dai W, Li Y.(2019). Potential associations of testosterone/estradiol ratio, leukocyte hTERT expression and PBMC telomerase activity with aging and the presence of coronary artery disease in men. *Exp Gerontol.* 2019;117:38–44. PMID: 30179663 DOI:10.1016/j.exger.2018.08.008

Received: 06-May-2019

Accepted: 13-Aug-2019